Microglial MS4A4A Protects against Epileptic Seizures in Alzheimer's Disease
Advanced Science · 2025-06 · 12 (22)
DOI: 10.1002/advs.202417733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.05.2025. Verfasst von Meng Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunology and School of Basic Medical Sciences and Beijing Key Laboratory of Immunological Research of Allergy (LIRA), Tsinghua Univer…. Hauptthemen laut MEDLINE: Alzheimer Disease, Microglia, Seizures, Epilepsy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a predominant neurodegenerative disorder worldwide, with epileptic seizures being a common comorbidity that can exacerbate cognitive deterioration in affected individuals, thus highlighting the importance of early therapeutic intervention. It is determined that deletion of Ms4a4a , an AD‐associated gene, exacerbates seizures in amyloid β (Aβ)‐driven AD mouse model. MS4A4A is significantly upregulated in brain lesions in patients with epilepsy. Single‐cell sequencing reveals that MS4A4A is highly expressed in microglia within these lesions, linked to enhanced phagocytic activity. Mechanistic investigation delineates that deletion of Ms4a4a impairs microglial phagocytosis, accompanied by diminished calcium influx and disruptions in mitochondrial metabolic fitness. The cytosolic fragment of Ms4a4a is anchored to the cytoskeletal components, supporting its critical role in mediating phagocytosis. Induction of Ms4a4a through central delivery of LNP‐ Il4 alleviates seizure conditions. Collectively, these findings identify Ms4a4a as a potential therapeutic target for managing seizures in AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Immunology and School of Basic Medical Sciences and Beijing Key Laboratory of Immunological Research of Allergy (LIRA), Tsinghua University, Beijing, 100084, China.
- School of Life Sciences, Tsinghua University, Beijing, 100084, China.
- ENO Bio mRNA Innovation Institute, Shenzhen Rhegen Biotechnology Co. Ltd, Shenzhen, 518000, China.
- Pediatric Epilepsy Center, Peking University First Hospital, Beijing, 100034, China.
- SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine, Taiyuan, 030001, China.
- Tsinghua-Peking Center for Life Sciences, Beijing, 100084, China.
ORCID-Profile: Wenwen Zeng
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Jiang, M., Li, Q., Chen, J., Li, R., Yao, J., Hu, Y., Zhang, H., Cai, L., Luo, M., Sun, Y., & Zeng, W. (2025). Microglial MS4A4A Protects against Epileptic Seizures in Alzheimer's Disease. Advanced Science, 12(22). https://doi.org/10.1002/advs.202417733
Vancouver
Jiang M, Li Q, Chen J, Li R, Yao J, Hu Y, et al. Microglial MS4A4A Protects against Epileptic Seizures in Alzheimer's Disease. Advanced Science. 2025;12(22). doi:10.1002/advs.202417733
BibTeX
@article{Jiang2025,
author = {Jiang, Meng and Li, Qingqing and Chen, Jianhui and Li, Ruochong and Yao, Jun and Hu, Yong and Zhang, Haizheng and Cai, Lixin and Luo, Maoguo and Sun, Yu and Zeng, Wenwen},
title = {Microglial MS4A4A Protects against Epileptic Seizures in Alzheimer's Disease},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {22},
doi = {10.1002/advs.202417733}
}
EUVIMED